San Antonio Breast Cancer Symposium 2024 provided multiple updates in the field of HER2-positive breast cancer, including ...
The Phase II portion is seeking to establish safety and efficacy of the company’s HER2 breast cancer therapy in combination ...
No improvement in overall survival (OS) was observed with palbociclib (Verzenio) plus endocrine therapy versus capecitabine ...
AstraZeneca AZN stock has risen 8.6% in the past month, mainly due to mixed fourth-quarter results and a positive update from ...
T-DM1 reduced risk of invasive disease events and death compared with trastuzumab in HER2-positive early breast cancer with ...
AstraZeneca and Daiichi Sankyo's HER2-directed antibody-drug conjugate Enhertu (trastuzumab deruxtecan) already has ...
OS Therapies (OSTX) announced that it received a notice of allowance from the United States Patent & Trademark Office that a patent will be ...
GlobalData on MSN1d
FDA grants priority review for Boehringer’s zongertinib NDA in NSCLCPriority review illustrates the urgent need in this patient population and the possibility for zongertinib to be a groundbreaking innovation for patients with limited treatment ...
Celcuity's gedatolisib, a dual PI3K/mTOR inhibitor, shows promise in Phase 3 breast cancer trials. Click here to read an ...
Dr. Debu Tripathy breaks down the FDA approval of Enhertu in unresectable or metastatic HR-positive, HER2-low or -ultralow ...
In a Phase Ib trial, 71 percent of patients responded to zongertinib and lived a median six months before disease progression or death.
Based on data from the Beamion LUNG-1 trial, the FDA granted a priority review to zongertinib for patients with HER2-mutant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback